Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MacroGenics, Inc. - Common Stock (NQ:MGNX)

1.580 -0.040 (-2.47%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about MacroGenics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
MacroGenics Revenue Doubles in Q2
Via The Motley Fool
Which stocks have an unusual volume on Wednesday?
Discover the stocks with unexpected trading volume in today's session on the US markets. 
Via Chartmill
Which stocks are gapping on Tuesday?
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Tuesday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
A Look at Macrogenics's Upcoming Earnings Report
 
Via Benzinga
Peeling Back The Layers: Exploring Macrogenics Through Analyst Insights
 
Via Benzinga
Macrogenics Earnings Preview
 
Via Benzinga
4 Analysts Assess Macrogenics: What You Need To Know
 
Via Benzinga
Why AZEK Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
MacroGenics (MGNX) Q4 2024 Earnings Call Transcript
MGNX earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Macrogenics Stock: A Deep Dive Into Analyst Perspectives (9 Ratings)
 
Via Benzinga
Evaluating Macrogenics: Insights From 8 Financial Analysts
 
Via Benzinga
Expert Outlook: Macrogenics Through The Eyes Of 7 Analysts
 
Via Benzinga
Earnings Scheduled For May 13, 2025
 
Via Benzinga
Earnings Scheduled For March 20, 2025
 
Via Benzinga
MacroGenics (MGNX) Q3 2024 Earnings Call Transcript
MGNX earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Demystifying Macrogenics: Insights From 14 Analyst Reviews
 
Via Benzinga
After Reporting Five Patient Deaths, Data Committee Recommends MacroGenics Halt Prostate Cancer Trial
MacroGenics will discontinue vobra duo for remaining mCRPC participants after five deaths. New data to be presented at ESMO 2024 conference. 
Via Benzinga
Topics Death
Match Group Layoffs 2024: What to Know About the Latest MTCH Job Cuts
Match Group layoffs are a hot topic on Wednesday as the dating website operator is preparing to reduce its headcount due to demand changes. 
Via InvestorPlace
Topics Workforce
Why is Macrogenics (MGNX) Stock Down 28% Today?
Macrogenics stock is down on Wednesday after MGNX investors learned that the company is discontinuing a Phase 2 clinical trial. 
Via InvestorPlace
Pinterest Issues Weak Revenue Forecast, Joins Groupon, O-I Glass And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to dive into the biggest pre-market stock movers for Wednesday as we check out all of the hottest news happening this morning! 
Via InvestorPlace
Why AMD Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
DexCom, Zynex, Olin And Other Big Stocks Moving Lower In Friday's Pre-Market Session
 
Via Benzinga
3 Biotech Stocks That Could Be Millionaire-Makers: May Edition
Investors should take a close look at these biotech stocks as they position themselves to provide high returns. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
 
Via Benzinga
Masters In Trading - Saturday, May 11
In this recap of the most recent trading session, I discuss earnings results and the market rally seen throughout the past week. 
Via Talk Markets
MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths'
Despite MacroGenics' clinical activity, unexpected adverse events raise concerns. Analysts adjust ratings and price targets. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.